Research Papers:

Identification of biomarkers for pseudo and true progression of GBM based on radiogenomics study

Xiaohua Qian, Hua Tan, Jian Zhang, Keqin Liu, Tielin Yang, Maode Wang, Waldemar Debinskie, Weilin Zhao, Michael D. Chan and Xiaobo Zhou _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:55377-55394. https://doi.org/10.18632/oncotarget.10553

Metrics: PDF 3536 views  |   HTML 2765 views  |   ?  


Xiaohua Qian1,*, Hua Tan1,*, Jian Zhang1, Keqin Liu1, Tielin Yang2, Maode Wang3, Waldemar Debinskie4, Weilin Zhao1, Michael D. Chan4, Xiaobo Zhou1

1Department of Radiology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA

2School of Life Science, Xi’an Jiaotong University, Xi’an, Shanxi 710049, China

3The First Affiliated Hospital, Xi’an Jiaotong University, Xi’an, Shanxi 710061, China

4Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA

*These authors have contributed equally to this work

Corresponding to:

Xiaobo Zhou, email: [email protected]

Keywords: GBM, pseudo and true tumor progression, radiogenomics, IRF9, XRCC1

Received: January 19, 2016    Accepted: May 05, 2016    Published: July 13, 2016


The diagnosis for pseudoprogression (PsP) and true tumor progression (TTP) of GBM is a challenging task in clinical practices. The purpose of this study is to identify potential genetic biomarkers associated with PsP and TTP based on the clinical records, longitudinal imaging features, and genomics data. We are the first to introduce the radiogenomics approach to identify candidate genes for PsP and TTP of GBM. Specifically, a novel longitudinal sparse regression model was developed to construct the relationship between gene expression and imaging features. The imaging features were extracted from tumors along the longitudinal MRI and provided diagnostic information of PsP and TTP. The 33 candidate genes were selected based on their association with the imaging features, reflecting their relation with the development of PsP and TTP. We then conducted biological relevance analysis for 33 candidate genes to identify the potential biomarkers, i.e., Interferon regulatory factor (IRF9) and X-ray repair cross-complementing gene (XRCC1), which were involved in the cancer suppression and prevention, respectively. The IRF9 and XRCC1 were further independently validated in the TCGA data. Our results provided the first substantial evidence that IRF9 and XRCC1 can serve as the potential biomarkers for the development of PsP and TTP.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10553